Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Mallinckrodt plc/Cadence Pharmaceuticals, Inc. tender offer
| February 10, 2014 • Antitrust Risk-shifting • $1.3 billion |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.